Friday, September 12, 2025

Latest

The Deep Dive Compiles Company Profile on Khiron Life Sciences

The Deep Dive has assembled a company profile for that of Khiron Life Sciences (TSXV: KHRN), a vertically integrated global medical and CPG cannabis leader with core operations in Latin America and Europe.

Khiron currently has distribution throughout various countries in Latin America, along with activity in North America and Europe. The company is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products from Colombia to UK, Peru and Uruguay/Brazil.

The overall thesis from our view can be broken into the following key points:

  1. Khiron is the early leader in Colombia with a fully vertical operation and regulatory ability and permits to export products internationally.
  2. Khiron stands out from their Latin American publicly traded competitors in terms of both revenue and balance sheet strength.
  3. They are the first to market with CBD cosmetic products in Colombia under the KUIDA brand.
  4. Khiron is one of a handful of suppliers producing medical cannabis products for distribution in the United Kingdom through Project Twenty21.
  5. The company has a balance sheet that gives them the strength to be careful and diligent within their growth strategy. More importantly, the balance sheet strength reduces shareholders dilution risk relative to vast majority of other cannabis companies.

Overall we feel Khiron is the leading distribution and service oriented company in a country that can offer the lowest cost cannabis products in the world and a huge base of patients. They have a prudent strategy to grab distribution in countries moving towards legalization and already have a proven suite of products available to plug into each new channel at industry leading costs of production.


FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Avino Q2 Earnings: Steady As She Goes

MEG Energy: Cenovus Comes In With $7.9 BILLION Offer

Orla Mining Q2 Earnings: Musselwhite Changes Everything

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

Khiron Life Sciences Announces German Cannabis Distribution Deal

Khiron Life Sciences (TSXV: KHRN) has signed a German distribution deal with that of Nimbus...

Thursday, June 25, 2020, 10:42:43 AM

Khiron Receives National Strategic Project Status From Colombian Government

This morning Khiron Life Sciences Corp (TSXV: KHRN) announced they received the status of National...

Tuesday, September 22, 2020, 09:43:55 AM

Khiron Life Sciences Records $2.8 Million In Revenue, $4.8 Million Net Loss In Q2 2021

Khiron Life Sciences Corp. (TSXV: KHRN) reported this morning its financial statements for the quarter...

Monday, August 23, 2021, 09:30:00 AM

Khiron Signs Exclusive Partnership with Rappi, The Amazon Of South America

Khiron Life Sciences (TSXV: KHRN) this morning announced the significant development of establishing an exclusive...

Friday, September 4, 2020, 08:17:02 AM

The Deep Dive Spotlight Series: Chris Naprawa of Khiron Life Sciences

The Deep Dive is stepping up our programming. We’re upgrading our Canadian small cap coverage...

Saturday, June 6, 2020, 09:00:00 AM